Efficacy and Safety of Bcl-2 Inhibitor Venetoclax in Hematological Malignancy: A Systematic Review and Meta-Analysis of Clinical Trials

Conclusion ： Venetoclax is a mild and efficient drug in treating advanced hematological malignancy which is specially fit for the CLL patients with del[17p], and AEs are well-tolerable. Few tumor lysis syndrome (TLS) occurred after taking the drugs. The AEs aroused by venetovlax and combination are well-tolerable. Therefore, the use of venetoclax monotherapy or its combination with other therapies is desirable in hematological malignancy.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research